Ongoing concerns about Avandia (rosiglitazone)

April 2010

Ongoing concerns about Avandia (rosiglitazone) will prompt more safety review by FDA....

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Respiratory & Allergy new controversy over treating asthma with long-acting beta-agonists (salmeterol, formoterol)
Men's Health Flomax (tamsulosin) is the first SELECTIVE alpha-blocker for benign prostatic hyperplasia (BPH) to go generic
Respiratory & Allergy whether certain inhalers need to be stored upright
Diabetes whether intensive treatment of blood pressure or lipids is beneficial for type 2 diabetes patients
Neurology & Pain Pennsaid, a new Rx topical diclofenac solution
Pediatrics whether CHILDREN should take fish oil supplements
Gastroenterology Which of these OTCs is NOT like the others...Maalox Advanced, Maalox Total Relief, or Pepto-Bismol
Geriatrics adjust med regimens to help avoid falls in the frail elderly
Statins Stronger warnings about an increased risk of myopathy will limit doses of simvastatin (Zocor, etc)
concerns about the safety of denture adhesives with zinc
whether cell phones, smart phones, and other electronic devices can interfere with hospital equipment
Diabetes Meds Ongoing concerns about Avandia (rosiglitazone)